Home » Stocks » EW

Edwards Lifesciences Corporation (EW)

Stock Price: $86.88 USD 0.99 (1.15%)
Updated Jan 26, 2021 3:17 PM EST - Market open
Market Cap 53.30B
Revenue (ttm) 4.37B
Net Income (ttm) 794.10M
Shares Out 622.10M
EPS (ttm) 1.27
PE Ratio 68.68
Forward PE 41.49
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $86.88
Previous Close $85.89
Change ($) 0.99
Change (%) 1.15%
Day's Open 84.41
Day's Range 84.03 - 87.84
Day's Volume 1,468,061
52-Week Range 52.41 - 91.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 6 days ago

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

PRNewsWire - 1 week ago

IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesd...

Seeking Alpha - 2 weeks ago

Edwards Lifesciences is a quality name that sits at the tip of the spear in cardiovascular value procedure offerings. The company has remained resilient in the face of the pandemic, and is wel...

PRNewsWire - 1 month ago

IRVINE, Calif., Dec. 21, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW), today announced that the first patient has been treated in the RESTORE clinical trial, which will evaluate the sa...

CNBC Television - 1 month ago

Edwards Lifesciences CEO on the state of elective surgeries amid pandemic

Edward Lifesciences CEO Mike Mussallem explained why he is concerned about how patients with structural heart disease are being treated for health issues as hospitals are overwhelmed by Covid-...

PRNewsWire - 1 month ago

IRVINE, Calif., Dec. 10, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeli...

InvestorPlace - 1 month ago

ESG investing can help create value both for society and shareholders. These seven ESG stocks are a good place to start.

Other stocks mentioned: CNHI, HAS, MSFT, NEE, OC, PLD
GuruFocus - 2 months ago

There are many useful nooks and crannies on the GuruFocus website, including screeners that help us find stocks outside the mainstream.

Other stocks mentioned: FNV, MASI
Seeking Alpha - 2 months ago

Strong Q3 exit with +6.4% growth in TAVR therapy sales, in spite of pressures from COVID-19. Shareholders have enjoyed +70% gains since March, however, with high volatility to the downside, wh...

Insider Monkey - 2 months ago

In this article we will take a look at whether hedge funds think Edwards Lifesciences Corporation (NYSE:EW) is a good investment right now. We check hedge fund and billionaire investor sentime...

Forbes - 3 months ago

Edwards expects to resume double digit growth as a robust product pipeline gets to market

Zacks Investment Research - 3 months ago

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.

Seeking Alpha - 3 months ago

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 13.33% and 5.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...

Investors Business Daily - 3 months ago

Edwards Lifesciences late Wednesday posted third-quarter sales that edged expectations and earnings per share that beat, but it hiked its earnings outlook only slightly and EW stock fell. The ...

Benzinga - 3 months ago

Shares of Edwards Lifesciences (NYSE:EW) decreased 2.5% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 63.83% year over year to $...

PRNewsWire - 3 months ago

IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2020. Third Quarter Highlights and Outlook Sa...

Zacks Investment Research - 3 months ago

These popular stocks have some of the best earnings charts of the week.

Other stocks mentioned: CMG, DHR, TSLA, WHR
Benzinga - 3 months ago

On Wednesday, October 21, Edwards Lifesciences (NYSE: EW) will release its latest earnings report. Here is Benzinga's outlook for the company.

Zacks Investment Research - 3 months ago

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 3 months ago

Robust customer adoption of the TruWave disposable pressure monitoring devices and the INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q3 revenues.

PRNewsWire - 3 months ago

IRVINE, Calif., Oct. 7, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW), plans to announce its operating results for the quarter ended September 30, 2020 after the market closes on Wednes...

GuruFocus - 3 months ago

According to the All-in-One Screener, a Premium feature of GuruFocus, five stalwarts that have high financial strength and expanding operating margins include Mastech Digital Inc. (MHH), Colum...

Other stocks mentioned: COLM, MASI, MED, MHH
Investors Business Daily - 4 months ago

Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.

Other stocks mentioned: ISRG, BSX, GH, NVCR
Zacks Investment Research - 5 months ago

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 5 months ago

TMO vs. EW: Which Stock Is the Better Value Option?

Other stocks mentioned: TMO
24/7 Wall Street - 5 months ago

Health care is supposed to be a very defensive sector in investing. After all, diseases and conditions such as cancer, diabetes, heart disease, kidney failure, dementia, joint damage and spina...

Other stocks mentioned: ABT, BAX, BSX, GMED, JNJ, MDT, NUVA, SYK
GuruFocus - 5 months ago

Last week, the Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the second quarter of the year.

Other stocks mentioned: BMY, CNC, NVS, UNH
Investors Business Daily - 6 months ago

Edwards Lifesciences handily topped Wall Street's second-quarter expectations amid a resurgence in heart-valve replacements. But EW stock struggled to edge closer to a buy point Friday.

Zacks Investment Research - 6 months ago

Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.

The Motley Fool - 6 months ago

But the coronavirus pandemic continues to create uncertainty for the medical device maker.

Seeking Alpha - 6 months ago

Edwards Lifesciences' (EW) CEO Mike Mussallem on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 126.67% and 18.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...

Benzinga - 6 months ago

Shares of Edwards Lifesciences (NYSE:EW) moved higher by 3.5% in after-market trading after the company reported Q2 results.

Investors Business Daily - 6 months ago

Late Thursday, Edwards Lifesciences reported adjusted income of 34 cents per share on $925 million in sales for its second quarter ended June 30. In response, EW stock popped.

PRNewsWire - 6 months ago

IRVINE, Calif., July 23, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monit...

Zacks Investment Research - 6 months ago

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 6 months ago

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 6 months ago

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

The Motley Fool - 6 months ago

The two companies' agreement puts to rest an escalating dispute over heart valve repair products.

Other stocks mentioned: ABT
Market Watch - 6 months ago

Abbott Laboratories ABT, +0.05% and Edwards Lifesciences Corp. EW, -0.92% said late Monday they settled a patent dispute with each other over certain heart valve repair products.

Other stocks mentioned: ABT
PRNewsWire - 6 months ago

IRVINE, Calif., July 13, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monit...

PRNewsWire - 6 months ago

IRVINE, Calif., July 9, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monito...

Zacks Investment Research - 6 months ago

Investors continue to be upbeat about Edwards Lifesciences (EW) owing to its strong segmental growth and robust product demand.

The Motley Fool - 6 months ago

Strong revenue growth and low debt make this stock a winner.

Zacks Investment Research - 7 months ago

Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.

PRNewsWire - 7 months ago

IRVINE, Calif., June 8, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monito...

Zacks Investment Research - 8 months ago

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 8 months ago

IRVINE, Calif., May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monito...

Investors Business Daily - 8 months ago

A Relative Strength Rating upgrade for Edwards Lifesciences shows improving technical performance. The post Stock Upgrades: Edwards Lifesciences Shows Rising Relative Strength appeared first o...

About EW

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aorti... [Read more...]

Industry
Medical Devices
IPO Date
Mar 27, 2000
CEO
Michael Mussallem
Employees
13,900
Stock Exchange
NYSE
Ticker Symbol
EW
Full Company Profile

Financial Performance

In 2019, EW's revenue was $4.35 billion, an increase of 16.79% compared to the previous year's $3.72 billion. Earnings were $1.05 billion, an increase of 44.96%.

Financial Statements

Analyst Forecasts

According to 25 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is 94.35, which is an increase of 8.60% from the latest price.

Price Target
$94.35
(8.60% upside)
Analyst Consensus: Buy